Introduction
Brand name: Uropod‑CV
Manufacturer: Astemax Biotech Pvt. Ltd. / Astelab United group
Product form: Cefixime 50 mg + Potassium clavulanate 28.5 mg oral suspension (orange flavour), reconstituted with Sterline Water (purified/sterile‑type water as directed)
Composition per 5 ml (after reconstitution)
Cefixime 50 mg
Potassium clavulanate 28.5 mg (equivalent to clavulanic acid ~20 mg in many formulations; exact equivalence depends on Astemax’s internal specification)
Key features and indications
Uropod‑CV is a broad‑spectrum β‑lactam combination suspension for children and select adults, indicated in bacterial infections resistant to oral cephalosporins alone, including:
Respiratory tract infections: Tonsillitis, pharyngitis, bronchitis, pneumonia.
Urinary tract infections (UTIs): Cystitis, uncomplicated pyelonephritis.
ENT infections: Otitis media, sinusitis.
Skin and soft‑tissue infections.
Mechanism:
Cefixime is a third‑generation oral cephalosporin that inhibits bacterial cell‑wall synthesis.
Potassium clavulanate is a β‑lactamase inhibitor that protects cefixime from degradation by enzyme‑producing resistant bacteria, thereby broadening its spectrum and reducing treatment failure risk.
Astemax positions Uropod‑CV as a WHO‑GMP‑oriented, paediatric‑friendly, broad‑spectrum suspension for community‑acquired infections where resistance to β‑lactams is suspected, with convenient orange‑flavoured, single‑step reconstitution via Sterline Water.
